Top Markets
#1 ALEO ALEO +7.58%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +5.79%
#3 TDCCP TDCCP +4.33%
#4 Cortex Cortex +4.27%
#5 Synapse Synapse +4.24%
#6 Steem Steem +3.89%
#7 MANTRA MANTRA +3.47%
#8 Moo Deng Moo Deng +3.47%
#9 Zilliqa Zilliqa +3.30%
#10 Ontology Gas Ontology Gas +3.07%
Coin of the day
ALEO ALEO
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Rang in aandelen #31262
Noxopharm Limited is an Australian drug development company with an... Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Aandeelprijs
$0.04443294
Marktkapitalisatie
$13.65M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-32.53%
Land
AU
Handel Noxopharm Limited (NOX)

Categorie

Healthcare
Winst voor Noxopharm Limited (NOX)
Winst in Jun 2026 TTM: $-4.15M
Volgens de meest recente financiële verslagen van Noxopharm Limited bedraagt de huidige winst van het bedrijf $-4.15M. In 2024 behaalde het bedrijf een winst van $-3.99M, een stijging ten opzichte van de winst van 2023, die $-14.02M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Noxopharm Limited van 2016 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-4.15M 29.05%
2025 $-3.22M -19.45%
2024 $-3.99M -71.53%
2023 $-14.02M -15.43%
2022 $-16.58M 136.55%
2021 $-7.01M 23.32%
2020 $-5.68M -50.43%
2019 $-11.46M -19.51%
2018 $-14.24M 507.24%
2017 $-2.35M 334.19%
2016 $-540.21K 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -127,225.42%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 74,296.89%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 96,690.59%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -47,110.79%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH